ELEDON PHARMACEUTICALS INC (ELDN) Stock Analyst Earnings Estimates
NASDAQ:ELDN - Nasdaq - US28617K1016 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 612.64% | N/A 88.71% | N/A -21.37% | N/A 113.04% | |||||||||||
| EBITDA YoY % growth | -23.44M | -45.15M -92.62% | -37.95M 15.95% | -13.1M 65.48% | -14.05M -7.25% | -14.17M -0.85% | -16.18M -14.18% | -36.87M -127.87% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -23.46M | -45.26M -92.92% | -38.12M 15.78% | -13.12M 65.58% | -14.06M -7.16% | -14.18M -0.85% | -16.19M -14.17% | -36.87M -127.73% | -39.78M -7.89% | -43M -8.09% | N/A -60.86% | N/A -29.58% | N/A -32.10% | N/A -46.44% | N/A -17.65% | N/A 7.50% | N/A 0.54% | N/A 13.04% | N/A 48.13% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -325.62 44.09% | -273.78 15.92% | N/A 85.58% | -28.08 28.86% | -22.86 18.59% | -13.21 42.22% | -2.32 82.43% | -2.76 -18.97% | -1.79 35.14% | N/A 63.72% | N/A -71.60% | N/A 4.81% | N/A 5.77% | N/A 2.04% | N/A 67.71% | N/A 167.74% | N/A | N/A |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.32 -11.85% | -0.26 24.00% | -0.29 73.06% | -0.34 -5.19% | -0.29 10.38% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -21.83M -111.17% | -22.785M -109.63% | -23.764M 6.33% | -25.622M -24.92% | -25.914M -18.70% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.32 8.57% | -0.32 | 0.00 | 0.40% |
| Q2 2024 Q2Q % growth | -1.06 -165.00% | -0.31 | -0.75 | -242.52% |
| Q1 2024 Q2Q % growth | -0.34 54.67% | -0.37 | 0.03 | 8.80% |
| Q4 2023 Q2Q % growth | -0.29 57.97% | -0.40 | 0.11 | 27.47% |
| Q3 2023 Q2Q % growth | -0.35 52.05% | -0.47 | 0.12 | 25.49% |
| Q2 2023 Q2Q % growth | -0.40 38.46% | -0.47 | 0.07 | 14.53% |
| Q1 2023 Q2Q % growth | -0.75 -8.70% | -0.61 | -0.14 | -22.75% |
| Q4 2022 Q2Q % growth | -0.69 -16.95% | -0.72 | 0.03 | 3.53% |
| Q3 2022 Q2Q % growth | -0.73 -10.61% | -0.69 | -0.04 | -5.25% |
| Q2 2022 Q2Q % growth | -0.65 -30.00% | -0.72 | 0.07 | 9.48% |
| Q1 2022 Q2Q % growth | -0.69 -21.05% | -0.69 | 0.00 | 0.15% |
| Q4 2021 Q2Q % growth | -0.59 72.14% | -0.77 | 0.18 | 22.88% |
| Q3 2021 Q2Q % growth | -0.66 88.02% | -0.66 | 0.00 | -0.16% |
| Q2 2021 Q2Q % growth | -0.50 76.85% | -0.58 | 0.08 | 13.62% |
| Q1 2021 Q2Q % growth | -0.57 83.33% | -0.33 | -0.24 | -74.63% |
| Q4 2020 Q2Q % growth | -2.12 34.63% | -1.42 | -0.70 | -49.03% |
| Q3 2020 Q2Q % growth | -5.51 -39.14% | -1.78 | -3.73 | -209.27% |
| Q2 2020 Q2Q % growth | -2.16 65.71% | -3.03 | 0.87 | 28.70% |
| Q1 2020 Q2Q % growth | -3.42 63.46% | -2.94 | -0.48 | -16.42% |
| Q4 2019 Q2Q % growth | -3.24 | -4.77 | 1.53 | 32.13% |
| Q3 2019 Q2Q % growth | -3.96 | -7.44 | 3.48 | 46.74% |
| Q2 2019 Q2Q % growth | -6.30 | -7.80 | 1.50 | 19.26% |
| Q1 2019 Q2Q % growth | -9.36 | -8.90 | -0.46 | -5.11% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -10.61% | -10.61% | 44.64% | 59.12% |
| Revenue | N/A | N/A | N/A | N/A |